The GLP-1 Drugs Have a Muscle Problem. Biohaven Thinks It Has the Fix.
Up to 40% of weight lost on GLP-1 drugs like semaglutide comes from lean muscle mass — a growing clinical concern for older patients and long-term users. Biohaven's taldefgrobep alfa, a myostatin-activin pathway inhibitor with a clean 700-patient safety record, just completed Phase 2 enrollment targeting fat loss with simultaneous muscle preservation. Phase 2 topline data expected 2H 2026 could reframe the obesity drug conversation.
GLP-1 drugs changed the obesity conversation permanently. Semaglutide and tirzepatide deliver weight loss numbers that no prior class of medicine could touch — 15%, 20%, even 22% of body weight in the best clinical data. Tens of millions of patients are on them. The market is projected at $100 billion by 2030.
But there is a problem hiding inside that success. Up to 40% of the weight people lose on GLP-1 agonists isn't fat — it's lean mass. Muscle. The tissue that governs metabolic rate, functional strength, insulin sensitivity, and long-term health outcomes. Patients are getting lighter, but not necessarily healthier in the ways that matter most beyond the scale.
Biohaven thinks it has a molecule that solves exactly this problem. And Phase 2 data expected in the second half of 2026 will determine whether that claim holds up in obese humans — not just in mice.
The GLP-1 muscle problem is real — and growing
Lean mass loss during GLP-1 therapy isn't a fringe concern. It is an increasingly well-documented consequence of rapid, caloric-restriction-driven weight loss. When the body sheds pounds at the pace GLP-1s induce, it draws on both adipose tissue and lean tissue simultaneously. Studies tracking body composition in semaglutide-treated patients consistently show lean mass reductions alongside fat mass reductions — in some cohorts, as much as 39% of total weight lost coming from lean tissue.
For young, otherwise healthy patients, this may be a manageable tradeoff. For older adults — where sarcopenia (age-related muscle loss) is already a significant driver of mortality, frailty, and metabolic dysfunction — losing an additional 5–8 lbs of lean mass while on a GLP-1 drug is not a trivial side effect. It is a meaningful clinical concern that complicates the risk-benefit calculation for the very populations most likely to need long-term obesity treatment.
The field has been aware of this for years. The answer, widely assumed, would come from combination therapy: pair a GLP-1 with something that builds or preserves muscle. Eli Lilly made the first major capital bet on this thesis in 2023, acquiring Versanis Bio and its bimagrumab program — an activin receptor antagonist — for up to $1.9 billion. Bimagrumab's Phase 2 data was striking: fat mass down 25.3%, comparable to high-dose semaglutide, while lean mass went up by 2.7% versus a 7.9% lean mass loss in the semaglutide arm. The problem: bimagrumab's safety profile — GI adverse events, muscle-related effects, unfavorable cholesterol changes — stalled further development as a standalone asset.
That is exactly where Biohaven's taldefgrobep enters the story.
What taldefgrobep actually does
Taldefgrobep alfa is a myostatin-activin pathway inhibitor (MAPI) — a fusion protein that blocks signaling through activin transmembrane receptors (ActRII) by targeting free myostatin and forming stable complexes that prevent downstream TGF-β ligand signaling. In plain language: myostatin is the protein that tells your muscles to stop growing. Taldefgrobep blocks that signal, shifting the body's composition equilibrium toward building and preserving lean tissue while simultaneously reducing adipose tissue accumulation.
The mechanism is not new. What distinguishes taldefgrobep from predecessor molecules like bimagrumab is its safety profile. Across more than 700 clinical trial participants — including Phase 3 data in spinal muscular atrophy — taldefgrobep has demonstrated rates of muscle- and GI-related adverse events comparable to placebo. No meaningful cholesterol signal. No high-frequency discontinuation. This is the clean safety record that bimagrumab lacked, and it is the reason Biohaven believes taldefgrobep can succeed where bimagrumab stumbled.
Phase 1 data in healthy adults already showed the direction: greater than 6% reduction in total body fat mass with commensurate increases in lean muscle mass of up to 4% — after just 29 days of dosing. Critically, body composition continued improving for four weeks after the final dose, suggesting the drug may support extended dosing intervals (once-monthly, not just weekly), a meaningful commercial differentiator in a market where adherence is everything.
The Phase 2 trial design
Enrollment in the Phase 2 proof-of-concept study completed in March 2026. The trial (NCT07281495) is a randomized, double-blind, placebo-controlled, dose-ranging study in approximately 150 adults with overweight or obesity across 20 US clinical sites. Participants receive taldefgrobep as monotherapy — either once-weekly or once-monthly via self-administered autoinjector — over a 24-week blinded treatment period followed by a 24-week open-label extension.
Primary endpoint: percent change in total body weight from baseline to Week 24. Secondary endpoints: percent change in total body fat mass and total lean mass — the two numbers that will either validate or complicate the entire thesis.
Topline data is expected in the second half of 2026. If the fat loss signal from Phase 1 translates to an obese population — and if lean mass either holds or increases — Biohaven will have demonstrated something the GLP-1 era has not yet produced: a monotherapy that makes patients lighter and metabolically stronger simultaneously.
The competitive landscape it's entering
Taldefgrobep is not the only asset targeting this space. Eli Lilly holds bimagrumab (safety concerns notwithstanding) and is almost certainly exploring combination studies with tirzepatide. Scholar Rock's apitegromab is in Phase 2 in combination with a GLP-1. Regeneron and others are watching myostatin biology closely. The underlying thesis — that the next generation of obesity therapy is about body composition quality, not just pounds lost — is now mainstream across the industry.
Biohaven's differentiator is the monotherapy positioning. Rather than positioning taldefgrobep as a GLP-1 add-on, the company is testing it as a standalone agent first. The preclinical combination data (additive benefit in obese mouse models when combined with a GLP-1) suggests the combination play is available if Phase 2 delivers — but the monotherapy data is the first gate. If taldefgrobep achieves meaningful weight loss with lean mass preservation or gain as monotherapy, it enters the conversation as an alternative for patients who cannot tolerate GLP-1s, who have plateaued on them, or for whom muscle preservation is the primary clinical concern.
That is a sizable and increasingly well-defined patient population. The 15 million Americans estimated to be on GLP-1 drugs are not a monolith. A meaningful subset are older adults, post-bariatric patients, or people with existing sarcopenia risk for whom lean mass loss is not an acceptable tradeoff. Taldefgrobep — if the data holds — is built for exactly them.
What the Phase 2 readout needs to show
The bar is clear. Taldefgrobep needs to demonstrate statistically significant total body weight reduction in an obese population — the primary endpoint regulators care about — while the secondary endpoints show favorable body composition (fat down, lean mass stable or up). A clean safety profile, consistent with the 700-patient track record, is table stakes.
If Phase 2 delivers on all three dimensions, Biohaven moves immediately into Phase 3 planning with a differentiated value proposition in the most competitive drug market on earth. If the weight loss signal is weaker than expected — or if the body composition benefit doesn't replicate in an obese population as clearly as in the leaner Phase 1 cohort — the story gets more complicated.
The second half of 2026 will answer the question. In a GLP-1 world that has proven weight loss is solvable, the next frontier is proving that the weight lost is the right weight.
Scientific Validity: 6/10 — Mechanism is well-understood (myostatin-activin pathway); clean 700+ participant safety database; Phase 1 body composition signal is directionally strong. Primary obesity efficacy data in an obese population does not yet exist — Phase 2 is the first real test in the target population.
Clinical Maturity: 4/10 — Phase 2 monotherapy study fully enrolled; topline data expected 2H 2026. Promising but pre-inflection.
Quad Label: High-Conviction Early Stage / Academic Darling — Strong mechanistic foundation, differentiated from GLP-1 class, and a clear unmet need. Phase 2 readout is the make-or-break moment.
Todd Colpron is the Managing Partner of Eliakim Capital, a boutique principal investment and strategic advisory firm focused on life sciences, capital strategy, and long-term value creation. He works with select management teams navigating growth, investor communications, and capital formation, while evaluating opportunities where Eliakim Capital’s experience, relationships, and investment perspective can add meaningful value. The firm may also invest its own capital when an opportunity demonstrates strong strategic alignment and investment merit.